Drug & Medication
Table of Contents
The 2011–20 projection period will see the loss of exclusivity for the leading non-insulin antidiabetic Actos franchise, while new launches include the first once-weekly GLP-1 agonists and the oral SGLT-2 inhibitor class, to compete in an increasingly crowded treatment algorithm in type 2 diabetes. This market research report was updated in May 2012 to reflect recent developments in the industry ....More »
The Largest Collection of Market Research Reports
From +200,000 authoritative sources
Talk to Shadi
+1 718 618 4897
REPORT HIGHLIGHTS The global market for ADC drugs reached $179 million in 2012 and $396 million in 2013. The market should reach $2.8 billion in 2018 with a compound annual growth rate (CAGR) of 48.1%. ...
The global equestrian market is a multi-billion dollar industry that comprises horse racing and betting, leisure and competitive riding and has spawned and supports multifarious secondary markets; the ...
The global ophthalmic drugs market is rapidly growing due to increasing prevalence of eye disorders such as glaucoma, dry eye diseases and retinal diseases. Changing lifestyle, improved medical infrastructure, ...
... Report description ophthalmic drugs market is expected to reach usd 21.6 Billion globally in 2018: transparency market research according to a new market report published by transparency ...
... The classes of medications not primarily used to preserve life or major body system functioning and thus of little or no value to the employer as well as those that may achieve outcomes of some value ...
Reportlinker.com © Copyright 2014. All rights reserved.